Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring Nov 05 | 2019WaveForm CGM Receives CE Mark; Senseonics Sensor RecallPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 05 | 2019Mylan and BD Q3 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 04 | 2019Tandem Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: SGLT2i Nov 04 | 2019Janssen Partners for Invokana DKD Promotion; BI/Lilly Update Alliance TermsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Nov 04 | 2019Novo Q3 '19 London Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Nov 01 | 2019Novo has a PCSK9i; Novo Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Oct 31 | 2019Sanofi Discontinues Tri-Agonist; Sanofi Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Oct 30 | 2019Thoughts on Verily/Onduo Novel Diabetes Life Insurance ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Oct 29 | 2019New Lilly Ph1 Trial; Likely GGG Tri-agonistPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Oct 28 | 2019Livongo to Add Telehealth Functionality; Roche Appoints new NA Diagnostics CEOPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery Oct 25 | 2019Omnipod Approved to use Novo's Fiasp; Senseonics Now Covered on HumanaPurchase Blast
$599
Posted in: Basal Insulin Oct 24 | 2019Biocon CY Q3 ’19 (FY Q2 ’20) Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Oct 24 | 2019AstraZeneca Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Oct 23 | 2019Lilly Q3 '19 Earnings Update; Conterno to RetirePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Oct 23 | 2019Thoughts on Medtronic Diabetes Leadership ChangePurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery Oct 23 | 2019Fiasp Approved for Pump Use in USPurchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
